Xiolife Pharmaceuticals And Healthcare Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 2.60 M
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -41.31%
- Profit Growth -43.96%
- Ebitda -981.72%
- Net Worth -31.82%
- Total Assets -17.92%
About Xiolife Pharmaceuticals And Healthcare
Xiolife Pharmaceuticals And Healthcare Private Limited (XPAHPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 August 2018 (Six years and five months 22 days old ). Its registered office is in Kamrup, Assam, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.60 M, as per Ministry of Corporate Affairs (MCA) records.
Arup Nath and Sandhyamika Devi serve as directors at the Company.
Company Details
-
Location
Kamrup, Assam, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85320AS2018PTC018673
-
Company No.
018673
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Aug 2018
-
Date of AGM
27 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Xiolife Pharmaceuticals And Healthcare?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arup Nath
|
Director | 21-Aug-2018 | Current |
|
Sandhyamika Devi
|
Director | 21-Aug-2018 | Current |
Financial Performance of Xiolife Pharmaceuticals And Healthcare.
Xiolife Pharmaceuticals And Healthcare Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 41.31% decrease. The company also saw a substantial fall in profitability, with a 43.96% decrease in profit. The company's net worth observed a substantial decline by a decrease of 31.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xiolife Pharmaceuticals And Healthcare?
In 2023, Xiolife Pharmaceuticals And Healthcare had a public holding of 28.85%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Mednomic Healthcare Private LimitedArup Nath and Sandhyamika Devi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xiolife Pharmaceuticals And Healthcare?
Unlock and access historical data on people associated with Xiolife Pharmaceuticals And Healthcare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xiolife Pharmaceuticals And Healthcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xiolife Pharmaceuticals And Healthcare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.